Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

MGNX
MacroGenics, Inc.
stock NASDAQ

Market Open
Aug 24, 2026 3:26:23 PM EDT
4.05USD-1.220%(-0.05)275,326
4.05Bid   4.06Ask   0.01Spread
Pre-market
Aug 24, 2026 9:25:30 AM EDT
4.10USD0.000%(0.00)283
After-hours
Aug 20, 2026 4:00:30 PM EDT
4.07USD+0.494%(+0.02)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Dec 27, 2021
08:01AM EST  I-Mab Announces IND Approval From China NMPA For Phase 2 Clinical Trial Of Enoblituzumab In Combination With Pembrolizumab In Solid Tumors   Benzinga
Nov 23, 2021
12:36PM EST  Macrogenics Shares See Volume; Co Reports In Form4 Filing Biotech Target Buys 200K Shares At Average Price Of $18.50/Share   Benzinga
Nov 16, 2021
10:05AM EST  MacroGenics Granted U.S. Patent Titled 'Combination therapy for the treatment of cancer'   Benzinga
Nov 3, 2021
04:01PM EDT  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following conferences in November and December 2021:   GlobeNewswire Inc
09:16AM EDT  JMP Securities Maintains Market Outperform on Macrogenics, Lowers Price Target to $38   Benzinga
Nov 2, 2021
04:17PM EDT  Macrogenics Q3 EPS $(0.86) Misses $(0.69) Estimate, Sales $15.70M Down From $18.25M YoY   Benzinga
04:01PM EDT  MacroGenics Provides Update on Corporate Progress and Third   GlobeNewswire Inc
10:54AM EDT  The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US   Benzinga
10:41AM EDT  Earnings Scheduled For November 2, 2021   Benzinga
Oct 31, 2021
02:24PM EDT  The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline   Benzinga
Oct 19, 2021
10:02AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021   Benzinga
07:03AM EDT  JMP Securities Initiates Coverage On Macrogenics with Market Outperform Rating, Announces Price Target of $39   Benzinga
Oct 2, 2021
03:07PM EDT  Last Week's Notable Insider Buys Included Evergy, Frontier Communications And More   Benzinga
Sep 28, 2021
08:54AM EDT  I-Mab (IMAB) said the Center for Drug Evaluation of China National Medical Products Administration has accepted the company's IND application to initiate a phase 2 trial for enoblituzumab in combination with pembrolizumab in patients with selected solid tumors. The phase 2 trial will evaluate the efficacy of the combination of enoblituzumab and pembrolizumab.   RTTNews
Sep 25, 2021
10:56AM EDT  Notable Insider Buys Of The Past Week Include Designer Brands, MacroGenics And More   Benzinga
Sep 16, 2021
02:46PM EDT  Mid-Afternoon Market Update: Dow Falls 70 Points; Aerie Pharmaceuticals Shares Plunge   Benzinga
02:19PM EDT  Macrogenics shares are trading lower after the company presented MGC018 at ESMO.   Benzinga
12:38PM EDT  Mid-Day Market Update: Gold Drops Over 2%; Leap Therapeutics Shares Jump   Benzinga
10:21AM EDT  Mid-Morning Market Update: Markets Down; US Retail Sales Unexpectedly Increase in August   Benzinga
02:45AM EDT  MacroGenics Announces Clinical Results from Cohort A Part 1 of   GlobeNewswire Inc
02:45AM EDT  MacroGenics Announces Preliminary Clinical Results from Phase 1   GlobeNewswire Inc
Sep 12, 2021
07:00PM EDT  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced poster presentations relating to multiple investigational product candidates at the European Society for Medical Oncology (ESMO) Virtual Conference, taking place September 16-21, 2021.   GlobeNewswire Inc
04:04PM EDT  The Week Ahead In Biotech (Sept. 12-18): Calliditas FDA Decision, Adcom Review For Pfizer/BioNTech COVID-19 Vaccine, Oncology Conference And IPOs   Benzinga
Sep 8, 2021
07:32AM EDT  The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod   Benzinga
Sep 7, 2021
04:31PM EDT  MacroGenics Announces Final Overall Survival Results From SOPHIA Study Of MARGENZA In Patients With HER2-Positive Metastatic Breast Cancer Did Not Demonstrate Statistically Significant Advantage For MARGENZA Over Trastuzumab   Benzinga
04:30PM EDT  MacroGenics Announces Final Overall Survival Results from SOPHIA   GlobeNewswire Inc
Sep 2, 2021
04:34PM EDT  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in thefollowing investor conferences in September:   GlobeNewswire Inc
Aug 19, 2021
11:42AM EDT  Macrogenics Option Alert: Oct 15 $25 Calls Sweep (17) near the Ask: 284 @ $2.55 vs 2286 OI; Ref=$21.93   Benzinga
Aug 6, 2021
10:54AM EDT  Looking into Macrogenics's Return on Capital Employed   Benzinga
Jul 29, 2021
04:50PM EDT  Macrogenics Q2 EPS $(0.66) Misses $(0.46) Estimate, Sales $30.76M Beat $30.03M Estimate   Benzinga
04:23AM EDT  Earnings Scheduled For July 29, 2021   Benzinga
Jul 22, 2021
04:05PM EDT  MacroGenics Announces Date of Second Quarter 2021 Financial   GlobeNewswire Inc
Jun 16, 2021
08:27AM EDT  MacroGenics, Zai Lab Ink Over $1.4B Immuno-Oncology Development Deal   Benzinga
07:33AM EDT  MacroGenics And Zai Lab Enter Collaboration To Develop And Commercialize Preclinical Bispecific Antibodies in Oncology; MacroGenics To Receive Initial Consideration Of $55M, An Equity Investment And Is Eligible For $1.4B In Milestones   Benzinga
07:30AM EDT  -- Zai Lab granted combination of regional Asian and global rights for up to four CD3- or CD47-based bispecific molecules -- MacroGenics provides rights to Zai Lab for its DART and TRIDENT multi-specific platforms and a lead research program targeting solid tumors -- Zai Lab provides rights to MacroGenics for certain intellectual property related to CD47 for select tumor targets   GlobeNewswire Inc
Jun 14, 2021
08:25PM EDT  Pomerantz LLP is investigating claims on behalf of investors ofMacroGenics, Inc. (MacroGenics or the Company) (NASDAQ:MGNX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
May 19, 2021
05:25PM EDT  Pharma/Biotech Companies Highlight Upcoming Presentations At American Society Of Clinical Oncology Jun. 4-8, 2021   Benzinga
05:05PM EDT  MacroGenics Announces Preliminary Clinical Results from Phase 1   GlobeNewswire Inc
07:00AM EDT  MacroGenics to Participate in Upcoming Investor Conference   GlobeNewswire Inc
Apr 30, 2021
08:37AM EDT  Morgan Stanley Maintains Underweight on Macrogenics, Raises Price Target to $17   Benzinga
06:47AM EDT  SVB Leerink Maintains Outperform on Macrogenics, Raises Price Target to $40   Benzinga
06:21AM EDT  HC Wainwright & Co. Maintains Buy on Macrogenics, Raises Price Target to $41   Benzinga
Apr 29, 2021
05:30PM EDT  Macrogenics Says May Offer And Sell Shares Of Common Stock Having Aggregate Offering Price Of Up To $200M From Time To Time   Benzinga
04:17PM EDT  Macrogenics Q1 EPS $(0.90) Misses $(0.61) Estimate, Sales $16.90M Up From $13.68M YoY   Benzinga
08:15AM EDT  The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx   Benzinga
04:10AM EDT  Earnings Scheduled For April 29, 2021   Benzinga
Apr 28, 2021
07:26AM EDT  The Daily Biotech Pulse: FDA Rejection For Protalix, Amgen Q1 Trail Estimates, Pfizer Goes Shopping   Benzinga
Apr 24, 2021
09:24AM EDT  The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx   Benzinga
Apr 23, 2021
07:28AM EDT  The Daily Biotech Pulse: Quidel Slides On Negative Pre-Announcement, Roche Gets Positive EMA Committee Recommendation, 3 IPOs   Benzinga
Apr 22, 2021
08:09AM EDT  The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs   Benzinga
Apr 21, 2021
07:31AM EDT  The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue   Benzinga
Apr 19, 2021
04:30PM EDT  MacroGenics Announces Date of First Quarter 2021 Financial Results   GlobeNewswire Inc
10:47AM EDT  Morgan Stanley Maintains Underweight on Macrogenics, Raises Price Target to $16   Benzinga
Apr 12, 2021
10:28AM EDT  Macrogenics Saturday Morning Announced Presentations At American Association For Cancer Research Conference   Benzinga
Apr 10, 2021
08:30AM EDT  MacroGenics, Inc.(Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 10-15, 2021.   GlobeNewswire Inc
Apr 9, 2021
06:31AM EDT  Provention Bio Stock Craters After FDA Flags Deficiencies In PK Profiles From Teplizumab Trials For Diabetes   Benzinga
Apr 7, 2021
07:58AM EDT  The Daily Biotech Pulse: FibroGen Fudges Safety Data, Novartis Strikes Cancer Drug Collaboration, Immutep Gains On Patent Award   Benzinga
Mar 23, 2021
08:18AM EDT  The Daily Biotech Pulse: FDA Approvals For Merck, Pacira And Zealand, Roche-Regeneron Ace Late-Stage COVID-19 Study, AlloVir Appoints Gilead Virology Chief As CEO   Benzinga
Mar 15, 2021
10:54AM EDT  I-Mab Poised To Capitalize On Growing Oncology Sector, Needham Says In Bullish Initiation   Benzinga
Mar 12, 2021
08:24AM EST  10 Biggest Price Target Changes For Friday   Benzinga
06:53AM EST  Barclays Upgrades Macrogenics to Overweight, Raises Price Target to $40   Benzinga
Feb 26, 2021
08:51AM EST  Morgan Stanley Maintains Underweight on Macrogenics, Raises Price Target to $15   Benzinga
07:30AM EST  MacroGenics to Participate in Upcoming Investor Conferences   GlobeNewswire Inc
Feb 25, 2021
04:03AM EST  Earnings Scheduled For February 25, 2021   Benzinga
Feb 23, 2021
07:25AM EST  The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts   Benzinga
Feb 11, 2021
04:43PM EST  MacroGenics Adds Federica O'Brien To Its Board   RTTNews
04:30PM EST  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer,today announced the appointment of FedericaFreddi OBrien, President ofCFOBrienConsulting, LLC, to its Board of Directors.   GlobeNewswire Inc
07:30AM EST  MacroGenics Announces Achievement of $10 Million Milestone Related   GlobeNewswire Inc
Feb 8, 2021
07:30AM EST  MacroGenics to Participate in Upcoming Investor Conferences   GlobeNewswire Inc
Jan 25, 2021
07:30AM EST  MacroGenics Announces Publication of SOPHIA Trial Results for   GlobeNewswire Inc
Jan 11, 2021
08:45AM EST  MacroGenics, Inc.(Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in January:   GlobeNewswire Inc
Jan 2, 2021
10:46AM EST  Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates   Benzinga
Dec 22, 2020
11:35AM EST  MacroGenics Announces MGD019 Publication in Cell Reports Medicine   GlobeNewswire Inc
06:13AM EST  H.C. Wainwright Assumes Macrogenics at Buy, Announces Price Target of $36   Benzinga
Dec 18, 2020
08:07AM EST  Benzinga Pro's Top 5 Stocks To Watch Friday, Dec. 18, 2020: BBVA, MGNX, FDX, AMGN, CYTH   Benzinga
07:54AM EST  MacroGenics Inc. (MGNX) said that it has reached a research collaboration and global license agreement to develop a preclinical bispecific molecule with Janssen Biotech Inc. The research collaboration will incorporate MacroGenics' proprietary DART platform to enable simultaneous targeting of two undisclosed targets in a therapeutic area outside oncology.   RTTNews
07:48AM EST  The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Vote, Mesoblast Sinks On Data   Benzinga
07:45AM EST  The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Approved, Mesoblast Sinks On Data   Benzinga
07:37AM EST  MacroGenics Enters Research Collaboration, Global License Agreement With Janssen Biotech   RTTNews
07:34AM EST  MacroGenics Enters Research Collaboration With Janssen To Develop Novel DART Molecule   Benzinga
07:30AM EST  MacroGenics Enters Research Collaboration with Janssen to Develop   GlobeNewswire Inc
Dec 17, 2020
01:27PM EST  Macrogenics shares were trading higher after the company announced FDA approval of MARGENZA for patients with pretreated metastatic HER2-positive breast cancer.   Benzinga
08:10AM EST  The Daily Biotech Pulse: MacroGenics Breast Cancer Drug Wins FDA Approval, Adcom Test Awaits Moderna, Virios To Make Wall Street Debut   Benzinga
06:04AM EST  A Peek Into The Markets: US Stock Futures Gain On Stimulus Hopes   Benzinga
Dec 16, 2020
10:33PM EST  MacroGenics Inc. (MGNX) said Wednesday that the U.S. Food and Drug Administration has approved Margenza, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.   RTTNews
08:15PM EST  Zai Lab Partner MacroGenics Announces FDA Approval of   GlobeNewswire Inc
04:33PM EST  MacroGenics Announces That The FDA Approved Its MARGENZA For Patients With Pretreated Metastatic HER2-Positive Breast Cancer   Benzinga
04:30PM EST  MacroGenics Announces FDA Approval of MARGENZA   GlobeNewswire Inc
Dec 13, 2020
04:27PM EST  The Week Ahead In Biotech: 2 IPOs Plus FDA Decisions On Moderna's COVID Vaccine And Drugs From Amgen, MacroGenics   Benzinga
Dec 7, 2020
07:35AM EST  MacroGenics Highlights Presentation Of Tebotelimab Data In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma At 2020 ASH Annual Meeting Dec. 5-8   Benzinga
07:30AM EST  -- 53.8% ORR in relapsed/refractory DLBCL patients -- Preliminary duration of response of up to 168 days observed, with six of seven ongoing responses as of cut-off date   GlobeNewswire Inc
Dec 6, 2020
04:12PM EST  MacroGenics Presented Flotetuzumab Data Showing Median Duration of Response of 8.13 Months in Patients with Refractory Acute Myeloid Leukemia at ASH 2020   Benzinga
01:00PM EST  -- 31.8% CR/CRh/CRi rate in primary induction failure and early relapsed AML patients -- Median duration of response = 8.13 months   GlobeNewswire Inc
08:41AM EST  Week Ahead In Biotech: FDA To Decide On Emergency Use Of Pfizer's COVID Vaccine, Hematology Conference Presentations Pick Up Pace   Benzinga
Dec 1, 2020
08:08AM EST  The Daily Biotech Pulse: Pfizer, BioNTech File Marketing Application In Europe, NuCana Jumps On Data, Amarin Takes On Hikma In Patent Lawsuit   Benzinga
Nov 30, 2020
04:30PM EST  MacroGenics Reports Deal With EVERSANA To Support Potential Launch, Commercialization Of Margetuximab   Benzinga
04:30PM EST  -- MacroGenics accesses EVERSANAs full suite of commercial services for which both parties share expenses -- EVERSANA may earn revenue share payments overfive years subject to predefined cap -- MacroGenics projected cash runway remains into 2023   GlobeNewswire Inc
07:30AM EST  MacroGenics Announces Achievement of $25 Million in Milestones   GlobeNewswire Inc
Nov 28, 2020
01:08PM EST  Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates   Benzinga
Nov 13, 2020
08:00AM EST  Morgan Stanley Maintains Underweight on Macrogenics, Raises Price Target to $14   Benzinga
Nov 8, 2020
03:58PM EST  The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions   Benzinga
12:47PM EST  The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs   Benzinga
Nov 5, 2020
04:04AM EST  SVB Leerink Maintains Outperform on Macrogenics, Lowers Price Target to $37   Benzinga
Nov 4, 2020
05:29PM EST  Macrogenics Filing Shows Registration For Mixed Shelf Offering Including $100M Common Stock Offering   Benzinga
04:27PM EST  Macrogenics: Q3 Earnings Insights   Benzinga
04:07PM EST  Macrogenics Q3 EPS $(0.66) Beats $(0.93) Estimate, Sales $18.25M Beat $15.79M Estimate   Benzinga
04:01PM EST  MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided an update on its corporate progress and reported financial results for the quarter ended September30, 2020.   GlobeNewswire Inc
02:34PM EST  MacroGenics Announces Flotetuzumab, Tebotelimab Presentations At The ASH Annual Meeting 2020   Benzinga
02:30PM EST  MacroGenics Announces Flotetuzumab and Tebotelimab Presentations   GlobeNewswire Inc
04:41AM EST  Earnings Scheduled For November 4, 2020   Benzinga
Oct 16, 2020
09:37AM EDT  Macrogenics Entered Into Commercial Supply Agreement With Incyte On Oct. 13   Benzinga
Oct 15, 2020
04:33PM EDT  MacroGeneics Announces Flotetuzumab Publication In Blood Advances   Benzinga
Oct 13, 2020
10:10AM EDT  Morgan Stanley Maintains Underweight on Macrogenics, Raises Price Target to $13   Benzinga
Sep 23, 2020
07:15AM EDT  -- Manuscript describes preclinical development of MGC018 -- Phase 1 dose expansion trial evaluating MGC018 in patients with mCRPC, TNBC and NSCLC is currently recruiting patients   GlobeNewswire Inc
Sep 22, 2020
04:30PM EDT  MacroGenics Highlights Publication Of Flotetuzumab Interim Phase 1/2 Clinical Trial Results   Benzinga
04:30PM EDT  MacroGenics Announces Publication of Flotetuzumab Interim Phase   GlobeNewswire Inc
Sep 21, 2020
08:23AM EDT  SVB Leerink Maintains Outperform on Macrogenics, Raises Price Target to $38   Benzinga
07:34AM EDT  MacroGenics Announces Receipt Of $15M Development Milestone Payment As Part Of Retifanlimab Collaboration With Incyte   Benzinga
07:32AM EDT  MacroGenics Says $15 Mln Milestone Triggered By Initiation Of Phase 3 Trial In NSCLC By Incyte   RTTNews
07:30AM EDT  -- $15 Million milestone triggered by initiation of Phase 3 clinical trial in NSCLC by Incyte   GlobeNewswire Inc
Sep 20, 2020
09:10AM EDT  -- MGD019 well-tolerated with early signals of activity in advanced solid tumors not typically responsive to checkpoint inhibition -- Recommended Phase 2 dose established for MSS CRC, NSCLC expansion cohorts -- Presentation is available on-demand as part of the ESMO Virtual Congress 2020   GlobeNewswire Inc
Sep 3, 2020
07:30AM EDT  MacroGenics to Participate in Upcoming Investor Conferences   GlobeNewswire Inc
Aug 3, 2020
09:32AM EDT  Benzinga's Top Upgrades, Downgrades For August 3, 2020   Benzinga
07:06AM EDT  Citigroup Downgrades Macrogenics to Neutral, Raises Price Target to $26   Benzinga
Jul 31, 2020
08:45AM EDT  Morgan Stanley Maintains Underweight on Macrogenics, Raises Price Target to $12   Benzinga
Jul 30, 2020
04:06AM EDT  Earnings Scheduled For July 30, 2020   Benzinga
Jul 23, 2020
07:30AM EDT  MacroGenics Announces Date of Second Quarter 2020 Financial   GlobeNewswire Inc
Jul 15, 2020
10:39AM EDT  Morgan Stanley Maintains Underweight on Macrogenics, Raises Price Target to $11   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC